RECRUITING

Psoriatic Immune Response to Tildrakizumab

Talk to us

Conditions

Psoriasis Vulgaris

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

Official Title

Psoriatic Immune Response to Tildrakizumab

Quick Facts

Study Start:2022-09-01
Study Completion:2025-09-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05390515

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 18 years of age or older
  2. * Patients with moderate-severe psoriasis or \> 5% body surface area affected.
  1. * taking systemic immunosuppressives in the last 4 weeks
  2. * pregnancy
  3. * severe immunodeficiency (either from genetic or infectious causes).
  4. * tuberculosis or other active serious infection
  5. * active systemic malignancy.
  6. * breast-feeding
  7. * Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Contacts and Locations

Study Contact

Raymond Cho, MD, PhD
CONTACT
415-575-0524
rashes@ucsf.edu

Principal Investigator

Raymond Cho, MD, PhD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

University of California, San Francisco
San Francisco, California, 94115
United States

Collaborators and Investigators

Sponsor: University of California, San Francisco

  • Raymond Cho, MD, PhD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-09-01
Study Completion Date2025-09-01

Study Record Updates

Study Start Date2022-09-01
Study Completion Date2025-09-01

Terms related to this study

Additional Relevant MeSH Terms

  • Psoriasis Vulgaris